Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care. GU Oncology Now spoke with Shyam Natarajan to discuss Avenda's iQuest and how AI can be used in the field of cancer care. Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy. Alexander Kutikov speaks about changes he pioneered in the GU surgical landscape and the future state of GU oncology care. Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment. Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape. Dr. Daniel Tennenbaum interviews Dr. Catherine H. Marshall on trends in managing advanced and metastatic prostate cancer. Dr. Catherine H. Marshall is interviewed on the use and future of chemotherapy for the treatment of advanced prostate cancer. Scott Eggener, MD gives an overview of focal therapy for prostate cancer, including its benefits and current research. Cell-based therapies have shown efficacy in disease settings, but for solid tumors, research has proceeded at a slower pace. David Ambinder, MD, speaks with Catherine Handy Marshall, MD, MPH on how to select treatments for prostate cancer. Benjamin Davies, MD, gives his insight on how to reduce the use of opiates for patients after urologic surgery. Dr. Cathy Marshall provides updates on prostate cancer clinical trial presentations for prostate cancer management.